Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice
- PMID: 14741225
- DOI: 10.1016/j.physbeh.2003.08.013
Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice
Abstract
The objective of the present study was to investigate the effects of the antiepileptic drug topiramate (TPM) on components of energy balance in lean and obese (ob/ob) mice in the presence or absence of leptin. Lean and ob/ob mice infused with either leptin or phosphate-buffered saline were treated with TPM for 7 days. TPM was mixed into the diet and administered at a dose of 60 mg/kg/day, whereas leptin was infused at the rate of 100 microg/kg/day using osmotic minipumps, which were subcutaneously implanted in the interscapular region. Food intake and body weight were monitored throughout the study. Body composition was measured prior to and following treatment with TPM and leptin, using dual-energy X-ray absorptiometry (DEXA). Glucose (glucose oxidase method) and insulin (radioimmunoassay) were also determined. TPM and leptin significantly reduced body weight gain, food intake and body fat gain in obese mice. The effects of TPM and leptin on fat gain were also statistically significant in lean animals. There was no interaction of TPM and leptin on the energy balance variables, the effects of the two substances being additive instead. Leptin abrogated hyperinsulinemia in obese mutants whereas TPM did not alter insulin levels in either lean or obese mice. The combination of leptin and TPM led to the normalization of glucose levels in obese mice. Our study demonstrates an effect of TPM in leptin-deficient animals, which suggests that TPM does not require the presence of leptin to exert its effect. They also show that the effects of leptin and TPM can be additive. The treatment with leptin in ob/ob mice neither accentuated nor blunted the effect of TPM on energy balance.
Similar articles
-
Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats.Obes Res. 2000 Dec;8(9):656-63. doi: 10.1038/oby.2000.84. Obes Res. 2000. PMID: 11225714
-
Effects of leptin adipose tissue lipoprotein lipase in the obese ob/ob mouse.Int J Obes Relat Metab Disord. 1998 Nov;22(11):1088-95. doi: 10.1038/sj.ijo.0800732. Int J Obes Relat Metab Disord. 1998. PMID: 9822947
-
Influence of topiramate in the regulation of energy balance.Nutrition. 2000 Oct;16(10):961-6. doi: 10.1016/s0899-9007(00)00452-4. Nutrition. 2000. PMID: 11054602 Review.
-
Effects of leptin on melanin-concentrating hormone expression in the brain of lean and obese Lep(ob)/Lep(ob) mice.Neuroendocrinology. 1999 Mar;69(3):145-53. doi: 10.1159/000054413. Neuroendocrinology. 1999. PMID: 10087446
-
Clinical aspects of leptin.Vitam Horm. 1998;54:1-30. doi: 10.1016/s0083-6729(08)60919-x. Vitam Horm. 1998. PMID: 9529971 Review.
Cited by
-
FTO is a relevant factor for the development of the metabolic syndrome in mice.PLoS One. 2014 Aug 21;9(8):e105349. doi: 10.1371/journal.pone.0105349. eCollection 2014. PLoS One. 2014. PMID: 25144618 Free PMC article.
-
Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.CNS Neurosci Ther. 2008 Summer;14(2):120-42. doi: 10.1111/j.1527-3458.2008.00041.x. CNS Neurosci Ther. 2008. PMID: 18482025 Free PMC article. Review.
-
Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations.Adv Ther. 2023 Sep;40(9):3626-3638. doi: 10.1007/s12325-023-02586-y. Epub 2023 Jun 27. Adv Ther. 2023. PMID: 37368102 Review.
-
Hypothalamic regulatory pathways and potential obesity treatment targets.Endocrine. 2006 Feb;29(1):33-48. doi: 10.1385/endo:29:1:33. Endocrine. 2006. PMID: 16622291 Review.
-
Role of antiepileptic drugs in the management of eating disorders.CNS Drugs. 2009;23(2):139-56. doi: 10.2165/00023210-200923020-00004. CNS Drugs. 2009. PMID: 19173373 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous